联合使用氨基水杨酸与溃疡性结肠炎患者升级至维得利珠单抗后结局改善无关
该研究评估口服氨基水杨酸联合维得利珠单抗治疗溃疡性结肠炎是否影响临床结局,基于临床试验数据比较联合与不联合氨基水杨酸患者的临床缓解、应答及黏膜愈合率,发现无显著差异。
要点
- 联合氨基水杨酸与维得利珠单抗治疗患者的临床缓解、应答及黏膜愈合率无显著差异。
- 此前英夫利西单抗或戈利木单抗试验中联合氨基水杨酸亦未显示显著差异。
- 升级至维得利珠单抗后是否继续氨基水杨酸尚不明确。
核心结论
- 联合使用口服氨基水杨酸与溃疡性结肠炎患者升级至维得利珠单抗后的临床结局改善无关。
研究设计与样本
- 基于维得利珠单抗治疗溃疡性结肠炎患者的临床试验数据,比较联合与不联合口服氨基水杨酸患者的临床结局。
主要发现
- 联合与不联合氨基水杨酸患者的临床缓解、临床应答及黏膜愈合率无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vedolizumab, a monoclonal antibody targeting α4β7 leukocyte integrins, has demonstrated efficacy for induction and maintenance of remission in ulcerative colitis (UC).1 However, it remains unclear whether oral aminosalicylates should be continued or stopped after treatment escalation to vedolizumab. Singh et al2 have demonstrated no significant difference in clinical remission, clinical response, or mucosal healing rates between patients treated with or without concomitant aminosalicylates at entry in clinical trials of infliximab or golimumab. We evaluate the impact of concomitant oral aminosalicylates on clinical outcomes for vedolizumab-treated UC patients.
引用
- Ma C, Kotze PG, Almutairdi A, et al. Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. Clin Gastroenterol Hepatol. 2018. PMID: 30528845. doi:10.1016/j.cgh.2018.11.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。